Alterity Therapeutics (ATHE) Research & Development (2015 - 2025)

Alterity Therapeutics' Research & Development history runs 10 years deep, the most recent figure standing at $4.3 million for Q4 2025.

• In Q4 2025, Research & Development rose 42.4% year-over-year to $4.3 million; the TTM figure through Dec 2025 stood at $15.6 million (up 1.7% YoY), while the FY2025 annual figure was $9.2 million, down 100.0% from the prior year.
• Research & Development was $4.3 million for Q4 2025 at Alterity Therapeutics, up from $3.0 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $4.3 million in Q4 2025 to a low of $3.0 million in Q4 2024.
• Historically, Research & Development has averaged $3.9 million across 5 years, with a median of $4.1 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Research & Development slipped 26.77% in 2024, then jumped 42.4% in 2025.
• A 5-year view of Research & Development shows it stood at $4.1 million in 2021, then rose by 2.3% to $4.2 million in 2022, then dropped by 0.23% to $4.1 million in 2023, then retreated by 26.77% to $3.0 million in 2024, then surged by 42.4% to $4.3 million in 2025.
• The last three Research & Development figures came in at $4.3 million (Q4 2025), $3.0 million (Q4 2024), and $4.1 million (Q4 2023), per Business Quant data.